RxDoctor Payments Data

Terngu Ibilah, MD

Psychiatry · Montgomery, ALNPI 1346761947

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 101 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$433
  • Vanda Pharmaceuticals Inc.$289
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
  • Neurocrine Biosciences, Inc.$172
  • Johnson & Johnson$160
  • Supernus Pharmaceuticals, Inc.$146
  • plus $828 from 13 others

What the payments were for

  • Food & beverage$2,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,235 in reported general payments places this provider in the 70th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$58,291
Medicare patients
339
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$42,160
Aripiprazole30$5,619
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine162$5,294
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine52$2,711
Quetiapine Fumarate100$1,936
Venlafaxine Hcl ErVenlafaxine Hcl44$1,819
Ziprasidone Hcl21$1,769
Bupropion XlBupropion Hcl41$1,719
Clonazepam292$1,682
Duloxetine Hcl65$1,659
Haloperidol Decanoate12$1,325
Trazodone Hcl87$1,262
Methylphenidate Hcl27$1,121
Buspirone Hcl37$851
Alprazolam263$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$433$42,16033 claims
Almatica Pharma LLCSertraline Hcl$19$57250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →